Skip to main content

Testing version — LOERadar is in active testing. Features and data may change.

Hub News Changes Search

LOERadar

FDA drug patent and exclusivity intelligence, assembled from public records.

Sponsored by

About Terms of Service Privacy Policy Log in

Attorney Advertising

© 2026 LOERadar · An informational research tool drawn from public records; it is not a law firm, does not provide legal advice, and its use does not create an attorney-client relationship.

RESERPINE AND HYDROFLUMETHIAZIDE (HYDROFLUMETHIAZIDE; RESERPINE) | LOERadar

Viewing data from:

RESERPINE AND HYDROFLUMETHIAZIDE

ANDA

HYDROFLUMETHIAZIDE; RESERPINE | A088907 | PAR PHARMACEUTICAL INC

1 strength0 unique patents0 unique exclusivities

Products (1)

#001 — 50MG;0.125MG

0 patents0 exclusivities▴

TABLET;ORAL | Approved: Sep 20, 1985

No patent or exclusivity listings for this strength.